BRCA mutated pancreatic cancer: A change is coming

Table 3 Ongoing phase II clinical trials investigating poly (ADP-ribose) polymerase inhibitor/Immune Checkpoint blockade combination therapy in pancreatic ductal adenocarcinoma

Study identifier	Patient population	Immunotherapy	PARP inhibitor	Phase and design	Estimated completion date
NCT03404960	Advanced PDAC patients who did not progress on PtCh	Nivolumab or Ipilimumab	Niraparib	Phase Ib/II trial evaluating effectiveness of olaparib with either nivolumab or ipilimumab	June 2021
NCT03851614	Advanced PDAC, leiomyosarcoma or mismatch repair-proficient colorectal cancer	Durvalumab	Olaparib	Phase II trial evaluating impact of combination therapy on genomic and immune biomarkers	March 2022
NCT04493060	Metastatic PDAC with mutations of BRCA1/2 or PALB2, previously treated with 1-2 lines of chemotherapy including a PtCh agent	Dostarlimab	Niraparib	Phase II, evaluating the disease control rate at 12 weeks (DCR12) with combination therapy	December 2022
NCT04548752	Metastatic PDAC with germline BRCA1 or BRCA2 mutation treated with first-line PtCh	Pembrolizumab	Olaparib	Phase II trial comparing combination therapy to olaparib alone as maintenance therapy	March 2025

PDAC: Pancreatic adenocarcinoma; PtCh: Platinum chemotherapy; BRCA: Breast cancer susceptibility gene.